RS51859B - Method for predicting the response to a treatment with a her dimerization inhibitor - Google Patents

Method for predicting the response to a treatment with a her dimerization inhibitor

Info

Publication number
RS51859B
RS51859B RS20110132A RSP20110132A RS51859B RS 51859 B RS51859 B RS 51859B RS 20110132 A RS20110132 A RS 20110132A RS P20110132 A RSP20110132 A RS P20110132A RS 51859 B RS51859 B RS 51859B
Authority
RS
Serbia
Prior art keywords
marker
growth factor
gene
alpha
transforming growth
Prior art date
Application number
RS20110132A
Other languages
Serbian (sr)
Inventor
Joachim Moecks
Andreas Strauss
Gerhard Zugmaier
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51859(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of RS51859B publication Critical patent/RS51859B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)

Abstract

METODA ZA PREDVIĐANJE ODGOVORA NA TRETMAN INHIBITORIMA DIMERIZACIJE HER, kod pacijenata koja obuhvata sledeće stupnjeve:a) određivanje, u uzorku biološkog materijala pacijenta, gde je taj uzorak krvni serum, nivoa ekspresije- marker proteina kodiranog marker genom za transformišući faktor rasta alfa ili- kombinacije marker proteina koju kodiraju marker geni, gde se kombinacija marker proteina koju kodiraju marker geni sastoji od marker proteina koje kodiraju- marker gen za transformišući faktor rasta alfa i za HER2,- marker gen za transformišući faktor rasta alfa i marker epidermalnog faktora rasta,- marker gen za amfiregulin i marker transformišućeg faktor rasta alfa- marker gen za transformišući faktor rasta alfa, epidermalni faktor rasta i marker HER2,- marker gen za amfiregulin, za epidermalni faktor rasta i marker transformišućeg faktora rasta alfa,- marker gen za amfiregulin, gen za transformišući faktor rasta alfa i marker HER2,- marker gen za epidermalni faktor rasta, transformišući faktor rasta alfa i marker HER2,- marker gen za amfiregulin, epidermalni faktor rasta, za transformišući faktor rasta alfa i marker HER2,b) za predviđanje odgovora na tretiranje pacijenta inhibitorom dimerizacije HER procenjivanjem rezultata stupnjeva a).Prijava sadrži još 14 patentnih zahteva.METHOD FOR PREDICTING RESPONSE TO TREATMENT WITH HER DIMERIZATION INHIBITORS, in patients comprising the following steps: a) determination, in a sample of the patient's biological material, where the sample is blood serum, marker proteins encoded by marker genes, where the combination of marker proteins encoded by marker genes consists of marker proteins encoded - marker gene for transforming growth factor alpha and for HER2, - marker gene for transforming growth factor alpha and marker of epidermal growth factor, - marker gene for amphiregulin and transforming growth factor marker alpha- marker gene for transforming growth factor alpha, epidermal growth factor and marker HER2, - marker gene for amphiregulin, for epidermal growth factor and marker of transforming growth factor alpha, - marker gene for amphiregulin, gene for transforming growth factor alpha and marker HER2, - marker gene for epidermal growth factor, transform alpha growth marker and HER2 marker, - marker gene for amphiregulin, epidermal growth factor, for transforming growth factor alpha and HER2 marker, b) for predicting response to treatment of a patient with HER dimerization inhibitor by evaluating the results of steps a). The application contains 14 more patent claims .

RS20110132A 2005-08-12 2006-05-24 Method for predicting the response to a treatment with a her dimerization inhibitor RS51859B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12

Publications (1)

Publication Number Publication Date
RS51859B true RS51859B (en) 2012-02-29

Family

ID=35511140

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110132A RS51859B (en) 2005-08-12 2006-05-24 Method for predicting the response to a treatment with a her dimerization inhibitor

Country Status (32)

Country Link
US (2) US7700299B2 (en)
EP (2) EP1915460B1 (en)
JP (1) JP2009504142A (en)
KR (2) KR20110074921A (en)
CN (2) CN101705287A (en)
AR (1) AR057323A1 (en)
AT (2) ATE493514T1 (en)
AU (2) AU2006281746B2 (en)
BR (1) BRPI0615001A2 (en)
CA (1) CA2616913A1 (en)
CL (1) CL2010000720A1 (en)
CR (1) CR9686A (en)
CY (1) CY1111612T1 (en)
DE (1) DE602006019265D1 (en)
DK (1) DK1915460T3 (en)
EC (1) ECSP088171A (en)
ES (1) ES2356066T3 (en)
HR (1) HRP20110171T1 (en)
IL (1) IL188923A0 (en)
MA (1) MA31549B1 (en)
MX (1) MX2008001926A (en)
NO (1) NO20080371L (en)
NZ (1) NZ565270A (en)
PL (1) PL1915460T3 (en)
PT (1) PT1915460E (en)
RS (1) RS51859B (en)
RU (2) RU2408735C2 (en)
SI (1) SI1915460T1 (en)
TW (1) TW200741010A (en)
UA (1) UA93989C2 (en)
WO (1) WO2007019899A2 (en)
ZA (1) ZA201102688B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
ATE441433T1 (en) 2000-05-19 2009-09-15 Genentech Inc GENETIC DETECTION METHOD TO IMPROVE THE PROBABILITY OF AN EFFECTIVE RESPONSE TO CANCER THERAPY WITH A HERITAGE ANTAGONIST
SV2006002143A (en) * 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
KR20070038557A (en) * 2004-07-22 2007-04-10 제넨테크, 인크. Her2 antibody composition
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
JP2008523073A (en) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Selection of patients for treatment with HER inhibitors
ZA200706017B (en) * 2005-01-21 2008-12-31 Genentech Inc Fixed dosing of her antibodies
EP1850874B1 (en) * 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (en) * 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
ATE520979T1 (en) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co BIOMARRKERS AND METHODS FOR DETERMINING SENSITIVITY TO MODULATORS OF THE EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR
MX2009008981A (en) * 2007-03-02 2009-09-02 Genentech Inc Predicting response to a her inhibitor.
JP5433189B2 (en) * 2007-09-28 2014-03-05 承一 尾崎 Method of providing material for predicting the effect of treatment on subjects with MPO-ANCA-related vasculitis
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
NZ586544A (en) * 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
CN102027135B (en) * 2008-03-14 2015-04-22 健泰科生物技术公司 Genetic variations associated with drug resistance
NZ589143A (en) 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
ES2535723T3 (en) 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Methods for determining the patient's response by measuring Her-3
CN102439452B (en) * 2009-01-15 2015-04-15 美国控股实验室公司 Methods of determining patient response by measurement of her-2 expression
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
EP2561356B1 (en) * 2010-04-18 2016-08-03 Yeda Research and Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CA2823397C (en) * 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
AU2012318541B2 (en) * 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
DK2766040T3 (en) 2011-10-14 2019-07-22 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early breast cancer
KR20190120430A (en) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 Biguanide compositions and methods of treating metabolic disorders
AU2013207329B2 (en) 2012-01-06 2017-10-26 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
BR112015024926A2 (en) 2013-04-16 2017-10-10 Genentech Inc compositions, article of manufacture, methods for treating a cancer patient, for evaluating a composition, for evaluating biological activity, for producing a composition and for evaluating the fragmentation of a composition and variant of pertuzumab
EP3027225B1 (en) * 2013-07-31 2021-03-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using transforming growth factor alpha
EP2876442A1 (en) 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
SG10201809411PA (en) 2014-04-25 2018-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2016011432A2 (en) 2014-07-17 2016-01-21 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
CN107614015A (en) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 Treat HER2 positives Locally Advanced or the previously method of untreated metastatic breast cancer
EP3325005A4 (en) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (en) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Fluorescence immunoassay detection method and kit for HER-2
KR20190075114A (en) 2016-11-04 2019-06-28 제넨테크, 인크. Treatment of HER2-positive breast cancer
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
EP3570884B1 (en) 2017-01-17 2020-09-30 Genentech, Inc. Subcutaneous her2 antibody formulations
WO2018160654A2 (en) 2017-03-02 2018-09-07 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
AU2019272190B2 (en) * 2018-05-25 2022-12-01 Bioneer Corporation Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
WO2024036234A1 (en) * 2022-08-09 2024-02-15 Heligenics Inc. Method for evaluating clinical relevance of genetic variance

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
AU4982097A (en) 1996-10-18 1998-05-15 Board Of Regents, The University Of Texas System Anti-erbb2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK2258872T3 (en) 2002-03-13 2013-11-18 Genomic Health Inc Gene expression profiling in tumor tissue biopsies
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
AU2003302821B2 (en) * 2002-12-11 2009-05-07 Cell Signaling Technology, Inc. Method for predicting the response to HER2-directed therapy
JP2006521793A (en) 2003-02-06 2006-09-28 ゲノミック ヘルス， インコーポレイテッド Gene expression marker responsive to EGFR inhibitor drug
JP2006521821A (en) 2003-04-01 2006-09-28 モノグラム バイオサイエンシズ，インコーポレーテッド Surface receptor complex as a biomarker
BRPI0410634A (en) 2003-05-30 2006-06-13 Astrazeneca Uk Ltd process
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
JP2007512807A (en) 2003-10-28 2007-05-24 バイエル ヘルスケア アーゲー Methods and compositions for predicting response to treatment of malignant tumors
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
JP2008523073A (en) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Selection of patients for treatment with HER inhibitors

Also Published As

Publication number Publication date
ATE539171T1 (en) 2012-01-15
TW200741010A (en) 2007-11-01
MA31549B1 (en) 2010-08-02
US7700299B2 (en) 2010-04-20
ATE493514T1 (en) 2011-01-15
EP1915460A2 (en) 2008-04-30
US20070037228A1 (en) 2007-02-15
AU2006281746B2 (en) 2011-06-23
WO2007019899A3 (en) 2007-04-05
CA2616913A1 (en) 2007-02-22
PT1915460E (en) 2011-03-17
RU2408735C2 (en) 2011-01-10
HRP20110171T1 (en) 2011-04-30
JP2009504142A (en) 2009-02-05
WO2007019899A8 (en) 2010-08-05
NO20080371L (en) 2008-05-09
KR20110074921A (en) 2011-07-04
MX2008001926A (en) 2008-03-24
CY1111612T1 (en) 2015-10-07
EP2196547A1 (en) 2010-06-16
CR9686A (en) 2008-02-20
NZ565270A (en) 2011-05-27
AU2011202339A1 (en) 2011-06-09
WO2007019899A2 (en) 2007-02-22
IL188923A0 (en) 2008-08-07
DK1915460T3 (en) 2011-01-31
DE602006019265D1 (en) 2011-02-10
RU2010115252A (en) 2011-10-27
ZA201102688B (en) 2012-01-25
UA93989C2 (en) 2011-03-25
KR20080034922A (en) 2008-04-22
US20100112603A1 (en) 2010-05-06
ES2356066T3 (en) 2011-04-04
CN101405405A (en) 2009-04-08
CN101705287A (en) 2010-05-12
EP2196547B1 (en) 2011-12-28
AR057323A1 (en) 2007-11-28
PL1915460T3 (en) 2011-05-31
RU2008108907A (en) 2009-09-20
CL2010000720A1 (en) 2010-12-03
AU2006281746A1 (en) 2007-02-22
BRPI0615001A2 (en) 2011-04-26
EP1915460B1 (en) 2010-12-29
ECSP088171A (en) 2008-03-26
SI1915460T1 (en) 2011-04-29

Similar Documents

Publication Publication Date Title
RS51859B (en) Method for predicting the response to a treatment with a her dimerization inhibitor
NO20074389L (en) Determination of responders to chemotherapy
Steyer et al. First histological and skeletochronological data on temnospondyl growth: palaeoecological and palaeoclimatological implications
NZ593226A (en) Gene expression markers (efnb2) for colorectal cancer prognosis
UA116618C2 (en) CONSTITUTION-BASED CYSTEINE ANTIBODY AGAINST CD79b
WO2006063042A3 (en) Selecting patients for therapy with a her inhibitor
EA200701426A1 (en) THE COMPOSITION OF THE TICKS, ITS APPLICATION, THE METHOD OF BREEDING THE PREDATORY MILE - PHYTOSEIDA AMBLYSEIUS SWIRSKII, THE SYSTEM FOR THE DEVELOPMENT OF THE SPECIFIED PREFERABLE TICKS AND THE METHOD OF BIOLOGICAL CONTROL OF THE PREVENTIVE TARGET
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
ATE538809T1 (en) METHOD FOR SELECTING APPROPRIATE PATIENTS FOR THE WT1 VACCINE
EA200701427A1 (en) THE COMPOSITION OF THE TICKETS, ITS APPLICATION, THE METHOD OF BREEDING THE PREDATORY MITCH - PHYTOSEID, THE SYSTEM FOR THE DEVELOPMENT OF THE SPECIFIED PREDATORY TICTION - PHYTOSEYIDE AND THE METHOD OF BIOLOGICAL CONTROL OF PESITURES
ATE459883T1 (en) NEW PROLIFERATION MARKERS IN CLINICAL PRACTICE AND THEIR USE FOR CANCER PROGNOSIS OR DIAGNOSIS
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
AR056125A1 (en) PROCEDURE FOR THE DIAGNOSIS OF THROMBOEMBOLIES AND ISCHEMICAL CARDIOPATIAS
ATE547534T1 (en) METHOD FOR THE NON-INVASIVE INVESTIGATION OF NON-ALCOHOLIC STEATOHEPATITIS USING QUANTIFICATION OF CYTOCHROME-C
DE602004027086D1 (en) CLASSIFICATION OF COLONY CANCER
DE602004029528D1 (en) Composition for the restoration of the vaginal ecosystem
ATE481644T1 (en) PREDICTION OF THE PROGRESS OF A CANCER DISEASE
DK1795897T3 (en) Predictive testing of therapeutic response for mammary cancer
AR056831A1 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES
DE602006020601D1 (en) PROCESS FOR USE OF IL-21
DE602005015599D1 (en) USE OF INTERLEUKIN-17 FOR OXYGEN TREATMENT
ATE497168T1 (en) METHOD FOR IN VITRO DIAGNOSIS OF GLIOMA OR ASTROCYTOMA AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA, ASTROCYTOMA OR RECURRENCE THEREOF
WO2009071841A3 (en) Egr1 modulators used in the treatment of alopecia
MY151438A (en) Compositions and method for treatment of tumors
WO2005096693A3 (en) Cancer prognosis and/or diagnosis method